Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 1 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2018 Filed Feb 27, 2018 22:26 UTC |
Kumar RameshDirector · President and CEO
|
GrantStock Option (right to purchase) · Derivative | 73,220 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001179110-18-002981 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,220 Underlying: Common Stock · 73,220 shares Expires 2028-02-23 F1 · derivative.exercise_date: This option grant was made in lieu of cash payment for a portion of Dr. Kumar's year-end bonus. The options vest immediately. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 00:12 UTC |
TYNDALL CAPITAL PARTNERS L P10% owner
|
PurchaseSeries A Convertible Preferred Stock Purchase Warrant · Derivative | 1,100,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000905718-18-000125 · onconova_fm4feb82018.xml · derivative · entry 2 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 1,100,000 Underlying: Series A Preferred Stock · 110,000 shares Expires not disclosed F2 · derivative.exercise_price: Each warrant ("Warrant") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the "Charter Amendment") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F2 · price: Each warrant ("Warrant") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the "Charter Amendment") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F4 · price: 1,100,000 Units purchased for $1.01 per Unit. Each Unit consists of one share of Common Stock and one Warrant. F3 · derivative.expiration_date: The Warrants are exercisable immediately and will expire on the later of (i) the one-year anniversary of the date (the "Charter Amendment Date") on which Issuer publicly announces through the filing of a Current Report on Form 8-K that the amendment to their certificate of incorporation to sufficiently increase their authorized shares of Common Stock to cover the conversion of all outstanding shares of Series A Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which Issuer publicly releases their top-line results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. F2 · derivative.underlying_shares: Each warrant ("Warrant") is exercisable into 0.1 share of Series A Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $1.01 per 0.1 share of Preferred Stock. Each 0.1 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). The Company does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of Series A Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Issuer must obtain stockholder approval of an amendment (the "Charter Amendment") to its Tenth Amended and Restated Certificate of Incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock. F3 · derivative.underlying_shares: The Warrants are exercisable immediately and will expire on the later of (i) the one-year anniversary of the date (the "Charter Amendment Date") on which Issuer publicly announces through the filing of a Current Report on Form 8-K that the amendment to their certificate of incorporation to sufficiently increase their authorized shares of Common Stock to cover the conversion of all outstanding shares of Series A Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which Issuer publicly releases their top-line results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 00:12 UTC |
TYNDALL CAPITAL PARTNERS L P10% owner
|
PurchaseCommon Stock | 1,100,000 | $1.01 | $1,111,000.00 |
DisclosureSEC source: 0000905718-18-000125 · onconova_fm4feb82018.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 2,097,022 F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:20 UTC |
MARINO JAMES JDirector
|
PurchaseWarrant (right to purchase) · Derivative | 50,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001179110-18-001967 · edgar.xml · derivative · entry 2 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Series A Convertible Preferred Stock · 5,000 shares Expires not disclosed F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374). F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and will expire on the later of (i) the one-year anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:20 UTC |
MARINO JAMES JDirector
|
PurchaseCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-001967 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,321 F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374). Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:37 UTC |
683 Capital Management, LLC10% owner
683 Capital Partners, LP10% owner
|
PurchaseCommon Stock, $0.01 par value | 200,000 | $1.04 | $207,120.00 |
DisclosureSEC source: 0001140361-18-006601 · doc1.xml · nonDerivative · entry 1 683 Capital Management, LLC · CIK 0001404574 · 10% owner 683 Capital Partners, LP · CIK 0001380126 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By 683 Capital Partners, LP Disclosed balance after: 2,664,934 F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:54 UTC |
Kumar RameshDirector · President and CEO
|
GrantStock Option (right to purchase) · Derivative | 64,885 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001179110-18-000604 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,885 Underlying: Common Stock · 64,885 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:51 UTC |
Maniar ManojSVP - Product Development
|
GrantStock Option (right to purchase) · Derivative | 28,609 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001179110-18-000603 · edgar.xml · derivative · entry 1 Maniar Manoj · CIK 0001642906 · SVP - Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,609 Underlying: Common Stock · 28,609 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:50 UTC |
Fruchtman Steven MChief Medical Officer
|
GrantStock Option (right to purchase) · Derivative | 43,627 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001179110-18-000602 · edgar.xml · derivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,627 Underlying: Common Stock · 43,627 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:49 UTC |
Guerin Mark PatrickChief Financial Officer
|
GrantStock Option (right to purchase) · Derivative | 31,024 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001179110-18-000601 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,024 Underlying: Common Stock · 31,024 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:07 UTC |
MARINO JAMES JDirector
|
GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008998 · edgar.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:09 UTC |
Bienen Henry SDirector
|
GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-009000 · edgar.xml · derivative · entry 1 Bienen Henry S · CIK 0001304250 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:08 UTC |
Hoffman Michael BDirector · 10% owner
|
GrantStock Option (right to purchase) · Derivative | 2,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008999 · edgar.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:04 UTC |
MEHTA VIRENDirector
|
GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008997 · edgar.xml · derivative · entry 1 MEHTA VIREN · CIK 0001238969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:04 UTC |
Reddy E PremkumarDirector
|
GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008996 · edgar.xml · derivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:00 UTC |
STOVER JACK EDirector
|
GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008993 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:00 UTC |
GROOPMAN JEROMEDirector
|
GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008992 · edgar.xml · derivative · entry 1 GROOPMAN JEROME · CIK 0001218853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:12 UTC |
Bienen Henry SDirector
|
PurchaseCommon Stock | 3,810 | $2.10 | $8,001.00 |
DisclosureSEC source: 0001179110-17-006250 · edgar.xml · nonDerivative · entry 1 Bienen Henry S · CIK 0001304250 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,724 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:11 UTC |
Guerin Mark PatrickChief Financial Officer
|
PurchaseCommon Stock | 1,429 | $2.10 | $3,000.90 |
DisclosureSEC source: 0001179110-17-006249 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,155 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:04 UTC |
MARINO JAMES JDirector
|
PurchaseCommon Stock | 11,906 | $2.10 | $25,002.60 |
DisclosureSEC source: 0001179110-17-006248 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,321 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:03 UTC |
Reddy E PremkumarDirector
|
PurchaseCommon Stock | 119,048 | $2.10 | $250,000.80 |
DisclosureSEC source: 0001179110-17-006247 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,832 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:03 UTC |
Kumar RameshDirector · President and CEO
|
PurchaseCommon Stock | 23,810 | $2.10 | $50,001.00 |
DisclosureSEC source: 0001179110-17-006246 · edgar.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,227 F1 · ownership.direct: 37,510 shares are held by the Ramesh Kumar 2012 Trust, of which the reporting person is a trustee. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 22:06 UTC |
TYNDALL CAPITAL PARTNERS L P10% owner
|
GrantCommon Stock | 476,190 | $2.10 | $999,999.00 |
DisclosureSEC source: 0000905718-17-000493 · tyndall_fm4apr212017.xml · nonDerivative · entry 1 TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 997,022 F1 · ownership.nature: As of April 21, 2017, Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"), held 997,022 shares of common stock, par value $0.01 per share ("Shares"), and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall Capital Partners L.P. ("Tyndall Capital"), and possesses the sole power to vote and the sole power to direct the disposition of all Shares and other securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:37 UTC |
Maniar ManojSVP - Product Development
|
GrantStock Option (right to purchase) · Derivative | 19,413 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001179110-17-001045 · edgar.xml · derivative · entry 1 Maniar Manoj · CIK 0001642906 · SVP - Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,413 Underlying: Common Stock · 19,413 shares Expires 2027-01-17 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:35 UTC |
Guerin Mark PatrickChief Financial Officer
|
GrantStock Option (right to purchase) · Derivative | 19,413 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001179110-17-001044 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,413 Underlying: Common Stock · 19,413 shares Expires 2027-01-17 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:32 UTC |
Kumar RameshDirector · President and CEO
|
GrantStock Option (right to purchase) · Derivative | 44,027 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001179110-17-001043 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,027 Underlying: Common Stock · 44,027 shares Expires 2027-01-17 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:30 UTC |
Fruchtman Steven MChief Medical Officer
|
GrantStock Option (right to purchase) · Derivative | 26,401 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001179110-17-001041 · edgar.xml · derivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,401 Underlying: Common Stock · 26,401 shares Expires 2027-01-17 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:42 UTC |
Fruchtman Steven MChief Medical Officer
|
GrantStock Option (right to purchase) · Derivative | 7,599 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033202 · edgar.xml · derivative · entry 1 Fruchtman Steven M · CIK 0001631251 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,599 Underlying: Common Stock · 7,599 shares Expires 2026-12-15 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:41 UTC |
Guerin Mark PatrickChief Financial Officer
|
GrantStock Option (right to purchase) · Derivative | 5,587 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033200 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587 Underlying: Common Stock · 5,587 shares Expires 2026-12-15 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:34 UTC |
Kumar RameshDirector · President and CEO
|
GrantStock Option (right to purchase) · Derivative | 12,673 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033197 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,673 Underlying: Common Stock · 12,673 shares Expires 2026-12-15 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:31 UTC |
Maniar ManojSVP - Product Development
|
GrantStock Option · Derivative | 5,587 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033196 · edgar.xml · derivative · entry 1 Maniar Manoj · CIK 0001642906 · SVP - Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587 Underlying: Common Stock · 5,587 shares Expires 2026-12-15 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.